A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

This study investigated the efficacy and safety of dacomitinib in advanced, refractory non–small cell lung cancer (NSCLC), selecting for patients with KRAS wild‐type tumors to exclude those least likely, and simultaneously enrich for those most likely, to benefit from therapy. Although the observed...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckamp, Karen L., Giaccone, Giuseppe, Camidge, D. Ross, Gadgeel, Shirish M., Khuri, Fadlo R., Engelman, Jeff A., Koczywas, Marianna, Rajan, Arun, Campbell, Alicyn K., Gernhardt, Diana, Ruiz‐Garcia, Ana, Letrent, Stephen, Liang, Jane, Taylor, Ian, O'Connell, Joseph P., Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164026/
https://www.ncbi.nlm.nih.gov/pubmed/24501009
http://dx.doi.org/10.1002/cncr.28561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164026/
https://www.ncbi.nlm.nih.gov/pubmed/24501009
http://dx.doi.org/10.1002/cncr.28561

Ejemplares similares